A European prospective observational study to evaluate fracture outcomes, back pain, health-related quality of life, and compliance in patients with osteoporosis during and after treatment with Forsteo® FRESH-PEF79-en A European prospective observational study to evaluate fracture outcomes, back pain, health-related quality of life, and compliance in patients with osteoporosis during and after treatment with Forsteo® EXFOS FRESH-PEF79-en 79 FRESH-PEF79 LILLY FRANCE Epidemiology France Portal (PEF) AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) null Osteoporotic patients teriparatide duration of treatment conditions of use Rheumatology Healthcare system determinants: Use of care Healthcare system determinants Primary objective: determine the incidence of clinical vertebral fractures and non-vertebral fragility fractures in patients treated with teriparatide for about 18 months and a post-treatment follow-up period of at least 18 months. Secondary objectives: observance, treatment switching and cessation, clinical evolution, occurrence of back pain, direct costs linked to fractures. null Croatia Denmark France Greece Italy Norway Slovenia Sweden Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Osteoporotic patients initiating treatment with teriparatide according to the practitioner's opinion in routine care Clinical data Participant-reported health data Health event/morbidity Health care consumption and services Quality of life/health perception Other Through independent healthcare practitioners [500-1000[ individuals Interview with the participant (including clinical) Observational Study Observational Study 1607 Unknown Restricted access Access on specific project only